



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 14/475, 1/107	A1	(11) International Publication Number: WO 98/03546 (43) International Publication Date: 29 January 1998 (29.01.98)
(21) International Application Number: PCT/US97/12609 (22) International Filing Date: 17 July 1997 (17.07.97) (30) Priority Data: 08/684,353 19 July 1996 (19.07.96) US (60) Parent Application or Grant (63) Related by Continuation US 08/684,353 (CIP) Filed on 19 July 1996 (19.07.96) (71) Applicant (for all designated States except US): AMGEN INC. [US/US]; Amgen Center, 1840 De Havilland Drive, Thousand Oaks, CA 91320-1789 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): BOONE, Thomas, C. [US/US]; 3010 Deer Valley Avenue, Newbury Park, CA 91320 (US). CHEUNG, Ellen, Ngoi, Yin [GB/US]; 4847 Aliano Drive, Agoura, CA 91301 (US). HERSHENSON, Susan, Irene [US/US]; 189 Heavenly Valley Road, Newbury Park, CA 91320 (US). YOUNG, John, David [US/US]; 2576 Sapra Street, Thousand Oaks, CA 91362 (US).		(74) Agents: ODRE, Steven, M. et al.; Amgen, Inc., Amgen Center, 1840 De Havilland Drive, Thousand Oaks, CA 91320-1789 (US). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: ANALOGS OF CATIONIC PROTEINS		
(57) Abstract		
<p>The <i>in vivo</i> circulating life and/or absorption of cationic therapeutic proteins, including but not limited to basic proteins such as NT-3 and BDNF, can be increased by generating analogs that have a lower isoelectric point and, preferably, also a lower protein charge relative to the protein of native sequence.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

ANALOGS OF CATIONIC PROTEINSFIELD OF THE INVENTION

5 This invention relates generally to polypeptide
analogs of therapeutically active cationic proteins,
including but not limited to analogs of the neurotrophic
factors known as neurotrophin-3 (NT-3) and brain-derived
neurotrophic factor (BDNF). More specifically, the
10 invention relates to positively charged polypeptides in
which modifications have been made in the native
sequence, such that the analogs possess lower
isoelectric points and, concomitantly, longer
circulation times and/or improved absorption *in vivo*
15 following parenteral administration. The invention also
relates to materials and methods for the recombinant
production of such polypeptide analogs, to antibodies
thereof, and to pharmaceutical compositions containing
the analogs which can be used for the treatment of
20 various diseases and disorders.

BACKGROUND OF THE INVENTION

 Following the administration of a therapeutic
25 protein by parenteral means, such as by subcutaneous,
intravenous or intramuscular injection, the
pharmacokinetic properties such as bioavailability,
circulation time and clearance rate can vary widely from
protein to protein. Even though there are active
30 efforts in many laboratories to develop alternative
routes of administration for protein products, little is
known about the factors that govern the pharmacokinetic
behavior of protein therapeutics following such
parenteral administration. It has been shown that an
35 increase in the molecular weight of a protein can result
in a preferential uptake by the lymphatic system rather

- 2 -

than the blood capillaries; Supersaxo et al.,
Pharmaceutical Res., Volume 7, page 167 et seq. (1990).
The molecular size of the therapeutic protein also plays
a key role in insulin uptake, where dissociation of a
5 zinc-induced hexamer to monomeric form has been shown to
be the rate-limiting step in insulin absorbance; Kang et
al., Diabetes Care, Volume 14, pages 942-948 (1991).
The clinical testing in diabetic patients of monomeric
insulin analogs, in which the hexamer association site
10 has been eliminated, has demonstrated a more rapid
uptake, leading to significant improvements in glucose
control in diabetic patients; see Brange et al., Nature,
Volume 333, page 679 et seq. (1988).

15 SUMMARY OF THE INVENTION

To assess the impact of the isoelectric point (pI)
on the pharmacokinetic behavior of proteins, certain
analogs of NT-3 and BDNF, in particular, have been
20 produced which have a relatively lower pI, yet retain
the structure and biological activity of the protein in
its "native" state (i.e., the protein of naturally
occurring amino acid sequence, as well as the met⁻¹
version thereof, both of which are referred to herein as
25 "wild type"). From these studies, it has now been
discovered that protein analogs engineered to possess a
lower pI and/or lower charge under physiological
conditions than the wild type molecule, can also display
longer *in vivo* circulation times (i.e., "half life") and
30 improved absorption following administration by
injection. Although the invention is illustrated in
this description with particular reference to human NT-3
and BDNF, it has broader applicability to any cationic
proteins, and particularly basic proteins which in their
35 native sequence have a pI greater than about 7.0.

- 3 -

It should be noted that the terms "protein" and "polypeptide" are used interchangeably throughout this description to mean one and the same thing.

5

Briefly stated, the present invention is concerned with substitution, insertion and deletion analogs of cationic therapeutic proteins, and/or chemically modified versions of such therapeutic proteins, that are characterized by a lower pI while also exhibiting longer circulation times and/or higher absorption relative to the unmodified proteins (i.e., of native sequence). The analog proteins of this invention are typically human therapeutic proteins which are usually, but not necessarily, basic proteins. Preferably, these proteins also have a lower charge under physiological conditions compared to the unmodified basic protein.

The present invention also concerns materials and methods for the recombinant production of such analogs (as a preferred practical method), as well as to antibodies raised against the protein analogs, and to pharmaceutical compositions containing the analogs as biologically active agents for use in the treatment of diseases and physical disorders.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGURE 1 shows the amino acid sequence for wild type human NT-3 (i.e., of "native" sequence) which has been produced recombinantly in *E. coli* bacterial cells and expressed with a methionine residue present at the N-terminus, i.e., r-metHuNT-3 (SEQ ID NO: 1). In the Figure, the amino acid numbering begins with the first

- 4 -

residue after the initial methionine (Met⁻¹), since the naturally occurring protein is normally expressed in mammalian cells without the methionine residue. (Note that Sequence Listing herein counts Met residue as +1).

5

FIGURE 2 shows the nucleic acid sequence (SEQ ID NO: 2, and Fig. 2A) and amino acid sequence (SEQ ID NO: 3, and Fig. 2B) of a polypeptide analog of r-metHuNT-3 of the present invention, namely,
10 NT-3₍₁₋₁₁₉₎R61A,K64D (with amino acid numbering in the Figure beginning with first residue after initial methionine).

FIGURE 3 shows the nucleic acid sequence (SEQ ID
15 NO: 4, and Fig. 3A) and amino acid sequence (SEQ ID NO: 5, and Fig. 3B) of another polypeptide analog of r-metHuNT-3 according to the present invention, namely, NT-3₍₁₋₁₁₇₎R61A,K64D (amino acid numbering in Figure again beginning with first residue after initial
20 methionine).

FIGURE 4 shows the ELISA assay calibration (standard) curves for wild type NT-3 (i.e., having SEQ ID NO: 1) and for the NT-3 analogs of SEQ ID NOS: 3 and
25 5. The optical density is plotted against sample concentration in nanograms per milliliter (ng/ml). The cross-reactivity to NT-3 analogs in the ELISA assay is approximately ten percent. Serum samples from pharmacokinetic studies were analyzed by ELISA, and
30 concentrations of wild type NT-3 and NT-3 analogs were determined by calibration against the appropriate standard curve.

FIGURE 5 depicts a size exclusion high performance
35 liquid chromatogram (SEC-HPLC) in which wild type NT-3

- 5 -

is compared to the NT-3 analogs of Figures 2 and 3. Units of absorbance ("AU") are plotted on the vertical axis, and the time of elution to the peak (in minutes) is shown on the horizontal axis. As shown, the analogs co-elute with the wild type molecule, demonstrating that the noncovalent dimer structure of wild type NT-3 has not been disrupted in either of the analogs. No aggregated protein was detected in any of these preparations. Figure legends: (_____) wild type NT-3; (----) NT-3₍₁₋₁₁₇₎R61A,K64D; and (____) NT-3₍₁₋₁₁₉₎R61A,K64D.

FIGURE 6 depicts a cation exchange high performance liquid chromatogram (CEX-HPLC) in which wild type NT-3 is compared to the NT-3 analogs of Figures 2 and 3. "AU" (vertical axis) indicates absorbance units. Time of elution to peak is shown on the horizontal axis. In this figure the analogs elute sooner than wild type NT-3, which is consistent with the lower isoelectric points of the analogs. Figure legends: (_____) wild type NT-3; (----) NT-3₍₁₋₁₁₇₎R61A,K64D; and (____) NT-3₍₁₋₁₁₉₎R61A,K64D.

FIGURE 7 depicts a silver stained SDS polyacrylamide gel electrophoresis (SDS-PAGE) chromatogram in which wild type NT-3 (see Figure 1) is compared to the NT-3 analogs of Figures 2 and 3. All three samples run as a single band with approximately the same molecular weight of the monomeric form. None of the samples are seen to contain significant amounts of higher molecular weight oligomers or lower molecular weight fragments. Lane 1: NT-3₍₁₋₁₁₇₎R61A,K64D, 2.5 µg; Lane 2: NT-3₍₁₋₁₁₉₎R61A,K64D, 2.5 µg; Lane 3; wild type NT-3, 2.5 µg; Lane 4: wild type NT-3, 12.5 µg; Lane 5: molecular weight markers.

- 6 -

FIGURE 8 shows the serum concentration (in nanograms per milliliter) versus time (in hours) profiles for the proteins of SEQ ID NOS: 1, 3 and 5 after intravenous (IV) administration to test rats. The dose level was 1 milligram per kilogram (mg/kg) of body weight. The concentration profiles are biphasic. The initial distribution phase was followed by a slower elimination phase. Each point on the graph represents an average of three animals.

FIGURE 9 shows the serum concentration (in nanograms per milliliter) versus time (in hours) curves in rats for the proteins of SEQ ID NOS: 1, 3 and 5 following subcutaneous (SC) administration of 1 mg/kg, with each point on the graph again representing an average of three animals. The absorption phase is characterized by an increase in serum concentration to a peak. Wild type NT-3 (SEQ ID NO: 1) showed the most rapid decline after attaining maximal concentration.

DETAILED DESCRIPTION OF THE INVENTION

The principles of this invention have broad applicability to any cationic proteins for which a reduction in the pI and, optionally, protein charge will result in an enhancement of therapeutically relevant biological properties such as circulation time and/or absorption following parenteral administration. By way of illustration, such proteins include but are not limited to basic proteins such as NT-3, BDNF, macrophage growth and differentiation factor and various known isoforms thereof having essentially the same ability to increase blood platelet production *in vivo* and *ex vivo* (referred to herein collectively as "MGDF"), and

- 7 -

keratinocyte growth factor (KGF). Detailed descriptions of these factors, their biological properties, and methods for their preparation and testing are given in the patent literature: NT-3 in published PCT application
5 WO 91/03569; BDNF in United States patents No.5,180,820, No.5,229,500, No.5,438,121 and No. 5,453,361, and in published PCT application WO 91/03568; MGDF in published PCT applications WO 95/26745, WO 95/21919, and WO 95/21920; and KGF in published PCT application
10 WO 90/08771.

In essence, the objective of this invention is to make one or more modifications to the primary structure of the wild type protein that preserve the protein
15 structure and biological activity of the protein, but which also results in a lower isoelectric point and, preferably, a lower charge at physiological pH. The particular way in which these modifications are made is not critical, and any procedure can be used which
20 effects the aforementioned changes to achieve the described enhancements in properties. Merely by way of illustration, appropriate modifications can be accomplished by use of site directed mutagenesis involving the addition of acidic residues to the
25 sequence by insertion and/or replacement mutations, and/or removal of basic residues by deletion and/or replacement mutations. Alternatively, chemical groups or moieties can be added to selected sites (i.e., on amino acid residues) in the protein chain of the wild
30 type molecule to accomplish the same end purpose (i.e., reduction of pI and charge with preservation of structure and biological activity). A specific example is the succinylation of selected residues in the protein chain.

35

- 8 -

Nucleic acids which encode protein analogs in accordance with this invention (i.e., wherein one or more amino acids are designed to differ from the wild type polypeptide) may be produced using site directed
5 mutagenesis or PCR amplification in which the primer(s) have the desired point mutations. For a detailed description of suitable mutagenesis techniques, see Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor,
10 NY (1989) and/or Ausubel et al., editors, Current Protocols in Molecular Biology, Green Publishers Inc. and Wiley and Sons, NY (1994). Chemical synthesis using methods described by Engels et al. in Angew. Chem. Intl. Ed., Volume 28, pages 716-734 (1989), may also be used
15 to prepare such nucleic acids.

The DNA molecules may be used to express the analog polypeptides of the invention by recombinant methods familiar to those skilled in the art, including but not
20 limited to methods described in the above mentioned patents or patent applications for NT-3, BDNF, KGF and MGDF. By way of illustration, a nucleic acid sequence encoding an analog polypeptide of this invention is inserted into an appropriate biologically functional
25 vector (e.g., circular plasmid or viral DNA) for expression in a suitable host cell. The vector includes regulatory sequences for expression of the inserted nucleic acid sequence and is selected to be functional in the particular host cell employed (i.e.,
30 the vector is compatible with the host cell machinery, such that amplification and/or expression of the gene can occur). The polypeptide may be amplified/expressed in prokaryotic, yeast, insect (baculovirus systems) and/or eukaryotic host cells. Selection of the host
35 cell will depend at least in part on whether the

- 9 -

polypeptide expression product is to be glycosylated. If glycosylation is desired, then yeast, insect or mammalian host cells are preferred for use.

5 Typically, the vectors will contain a 5' flanking sequence (also referred to as a "promoter") and other regulatory elements, as well as enhancer(s), an origin of replication element, a transcriptional termination element, a complete intron sequence containing a donor
10 and acceptor splice site, a signal peptide sequence, a ribosome binding site element, a polyadenylation sequence, a polylinker region for inserting the nucleic acid encoding the polypeptide to be expressed, and a selectable marker element.

15 The 5' flanking sequence may be the innate 5' flanking sequence from the wild type gene, or it may be homologous (i.e., from the same species and/or strain as the host cell), heterologous (i.e., from a species other
20 than the host cell species or strain), hybrid (i.e., a combination of 5' flanking sequences from more than one source), or synthetic. The source of the 5' flanking sequence may be any unicellular prokaryotic or eukaryotic organism, any vertebrate or invertebrate
25 organism, or any plant, provided that the 5' flanking sequence is functional in, and can be activated by, the host cell machinery.

 The origin of replication element is typically a
30 part of prokaryotic expression vectors purchased commercially, and aids in the amplification of the vector in a host cell. Amplification of the vector to a certain copy number can, in some cases, be important for optimal expression of the polypeptide. If the vector of
35 choice does not contain an origin of replication site,

- 10 -

one may be chemically synthesized based on a known sequence and then ligated into the vector.

5 The transcription termination element is typically located 3' to the end of the polypeptide coding sequence and serves to terminate transcription of the polypeptide. Usually, the transcription termination element in prokaryotic cells is a G-C rich fragment followed by a poly-T sequence. While the element is
10 easily cloned from a library or even purchased commercially as part of a vector, it can also be readily synthesized using methods for nucleic acid synthesis such as those referred to above.

15 A selectable marker gene element encodes a protein necessary for the survival and growth of a host cell grown in a selective culture medium. Typical selection marker genes encode proteins that (a) confer resistance to antibiotics or other toxins, e.g., ampicillin,
20 tetracycline, or kanamycin for prokaryotic host cells, (b) complement auxotrophic deficiencies of the cell; or (c) supply critical nutrients not available from complex media. Preferred selectable markers are the kanamycin resistance gene, the ampicillin resistance gene, and the
25 tetracycline resistance gene.

 The ribosome binding element, commonly called the Shine-Dalgarno sequence (for prokaryotes) or the Kozak sequence (for eukaryotes), is necessary for the
30 initiation of translation for mRNA. The element is typically located 3' to the promoter and 5' to the coding sequence of the polypeptide to be synthesized. The Shine-Dalgarno sequence is varied but is typically a polypurine (i.e., having a high A-G content). Many
35 Shine-Dalgarno sequences have been identified, each of

- 11 -

which can be readily synthesized using methods set forth above and used in a prokaryotic vector.

In those cases where it is desirable for the
5 polypeptide to be secreted from the host cell, a signal
sequence may be used to direct the polypeptide out of
the host cell where it is synthesized. Typically, the
signal sequence is positioned in the coding region of
nucleic acid sequence, or directly at the 5' end of the
10 coding region. Many signal sequences have been
identified, and any of them that are functional in the
selected host cell may be used here. Consequently, the
signal sequence may be homologous or heterologous to the
polypeptide. Additionally, the signal sequence may be
15 chemically synthesized using methods such as those
referred to set above.

Host cells may be prokaryotic host cells (such as
E. coli) or eukaryotic host cells (such as yeast, insect
20 or vertebrate cells). The host cell, when cultured
under suitable nutrient conditions, can synthesize the
polypeptide, which can subsequently be collected by
isolation from the culture medium (if the host cell
secretes it into the medium) or directly from the host
25 cell producing it (if not secreted). After collection,
the polypeptide can be purified using methods such as
molecular sieve chromatography, affinity chromatography,
and the like. In general, if the polypeptide is
expressed in *E. coli* it will contain a methionine
30 residue at the N-terminus in its recovered form (i.e.
met⁻¹), unless expressed in a strain of *E. coli* in which
the methionine is enzymatically cleaved off by the host.

Suitable cells or cell lines may also be mammalian
35 cells, such as Chinese hamster ovary cells (CHO) or 3T3

- 12 -

cells. The selection of suitable mammalian host cells and methods for transformation, culture, amplification, screening and product production and purification are known in the art. Other suitable mammalian cell lines are the monkey COS-1 and COS-7 cell lines, and the CV-1 cell line. Further exemplary mammalian host cells include primate cell lines and rodent cell lines, including transformed cell lines. Normal diploid cells, cell strains derived from *in vitro* culture of primary tissue, as well as primary explants, are also suitable. Candidate cells may be genotypically deficient in the selection gene, or they may contain a dominantly acting selection gene. Still other suitable mammalian cell lines include but are not limited to, HeLa, mouse L-929 cells, 3T3 lines derived from Swiss, Balb-c or NIH mice, BHK or HaK hamster cell lines.

Insertion (also referred to as "transformation" or "transfection") of the vector into the selected host cell may be accomplished using calcium chloride, electroporation, microinjection, lipofection or the DEAE-dextran method. The method selected will in part be a function of the type of host cell to be used. These methods and other suitable methods are well known to the skilled artisan, and are set forth, for example, in Sambrook et al., above.

The host cells containing the vector may be cultured using standard media well known to the skilled artisan. The media will usually contain all of the nutrients necessary for the growth and survival of the cells. Suitable media for culturing *E. coli* cells are, for example, Luria Broth (LB) and/or Terrific Broth (TB). Suitable media for culturing eukaryotic cells are RPMI 1640, MEM, DMEM, all of which may be supplemented

- 13 -

with serum and/or growth factors as required by the particular cell line being cultured. A suitable medium for insect cultures is Grace's medium supplemented with yeastolate, lactalbumin hydrolysate and/or fetal calf
5 serum as necessary.

Typically, an antibiotic or other compound useful for selective growth of the transformed cells is added as a supplement to the media. The compound to be used
10 will be dictated by the selectable marker element present on the plasmid with which the host cell was transformed. For example, where the selectable marker element is kanamycin resistance, the compound added to the culture medium will be kanamycin.

15 The amount of polypeptide produced in the host cell can be evaluated using standard methods known in the art. Such methods include, without limitation, Western blot analysis, SDS-polyacrylamide gel electrophoresis, non-denaturing gel electrophoresis, HPLC separation,
20 immunoprecipitation, and/or activity assays such as DNA binding gel shift assays.

If the polypeptide has been designed to be secreted
25 from the host cells, the majority of polypeptide will likely be found in the cell culture medium. If, however, the polypeptide is not secreted, it will be present in the cytoplasm (for eukaryotic, Gram-positive bacteria, and insect host cells) or in the periplasm
30 (for Gram-negative bacteria host cells).

For intracellular polypeptide, the host cells are typically first disrupted mechanically or osmotically to release the cytoplasmic contents into a buffered
35 solution. The polypeptide is then isolated from this

- 14 -

solution. Purification of the polypeptide from solution can thereafter be accomplished using a variety of techniques. If the polypeptide has been synthesized such that it contains a tag such as Hexahistidine or other small peptide at either its carboxyl or amino terminus, it may be purified in a one-step process by passing the solution through an affinity column where the column matrix has a high affinity for the tag or for the polypeptide directly (i.e., a monoclonal antibody). For example, polyhistidine binds with great affinity and specificity to nickel, thus an affinity column of nickel (such as the Qiagen nickel columns) can be used for purification. (See, for example, Ausubel et al., eds., Current Protocols in Molecular Biology, John Wiley & Sons, New York, 1994).

Where, on the other hand, the polypeptide has no tag and no antibodies are available, other well known procedures for purification can be used. Such procedures include, without limitation, ion exchange chromatography, molecular sieve chromatography, HPLC, native gel electrophoresis in combination with gel elution, and preparative isoelectric focusing ("Isoprime" machine/technique, Hoefer Scientific). In some cases, two or more of these techniques may be combined to achieve increased purity.

If it is anticipated that the polypeptide will be found primarily in the periplasmic space of the bacteria or the cytoplasm of eukaryotic cells, the contents of the periplasm or cytoplasm, including inclusion bodies (e.g., Gram-negative bacteria) if the processed polypeptide has formed such complexes, can be extracted from the host cell using any standard technique known to the skilled artisan. For example, the host cells can be

- 15 -

lysed to release the contents of the periplasm by the use of a French press, homogenization, and/or sonication. The homogenate can then be centrifuged.

5 In addition to preparing the polypeptide analogs of this invention by recombinant DNA techniques, the polypeptides may be prepared by chemical synthesis methods (such as solid phase peptide synthesis) using techniques known in the art, including those set forth
10 by Merrifield et al. in J. Am. Chem. Soc., Volume 85, page 2149 (1964), by Houghten et al. in Proc. Natl. Acad. Sci. USA, Volume 82, page 5132 (1985), and by Stewart and Young in Solid Phase Peptide Synthesis, Pierce Chem. Co, Rockford, IL (1984). Chemically
15 synthesized polypeptides may be oxidized using methods set forth in these references to form disulfide bridges.

 The pI and charge of the protein analogs resulting from any of the aforementioned methods can be measured
20 using standard techniques, such as those described further below in conjunction with the specific embodiments.

 Chemically modified polypeptide compositions (i.e.,
25 "derivatives") where the polypeptide is linked to a polymer in order to modify properties are included within the scope of the present invention. The polymer is typically water soluble so that the protein to which it is attached does not precipitate in an aqueous
30 environment, such as a physiological environment. The polymer may have a single reactive group, such as an active ester for acylation or an aldehyde for alkylation, so that the degree of polymerization may be controlled. A preferred reactive aldehyde is
35 polyethylene glycol propionaldehyde, which is water

- 16 -

stable, or mono C1-C10 alkoxy or aryloxy derivatives thereof (see U.S. Patent 5,252,714). The polymer may be branched or unbranched. Preferably, for therapeutic use of the end-product preparation, the polymer will be
5 pharmaceutically acceptable. The water soluble polymer, or mixture thereof if desired, may be selected from the group consisting of, for example, polyethylene glycol (PEG), monomethoxy-polyethylene glycol, dextran, cellulose, or other carbohydrate based polymers, poly-
10 (N-vinyl pyrrolidone) polyethylene glycol, propylene glycol homopolymers, a polypropylene oxide/ethylene oxide co-polymer, polyoxyethylated polyols (e.g., glycerol) and polyvinyl alcohol.

15 In general, the polypeptide analogs of this invention will be useful for the same purposes for which the wild type proteins from which they are derived are known to be useful. For instance, NT-3 is currently under clinical study for the treatment of peripheral
20 (including diabetic) neuropathies, while BDNF is under clinical study for the treatment of amyotrophic lateral sclerosis (ALS). KGF is known to be active as a tissue growth and repair factor, and is currently in human clinical development for the treatment of chemotherapy-
25 or radiation-induced mucositis. MGDF (in the form of a pegylated derivative) is in clinical development for the stimulation of platelet production as an adjunct to chemotherapy-induced thrombocytopenia. However, it is expected that the analogs of this invention will offer
30 advantages over the unmodified forms from the standpoint of enhanced therapeutic half life and absorbability.

For therapeutic purposes, the analog polypeptides of this invention will typically be formulated into
35 suitable pharmaceutical compositions adapted for

- 17 -

therapeutic delivery, which constitutes an additional aspect of this invention. Such pharmaceutical compositions will typically comprise a therapeutically active amount of an analog polypeptide, alone or
5 together with one or more excipients, carriers, or other standard ingredients for a pharmaceutical composition. The carrier material may be water for injection, preferably supplemented with other materials common in solutions for administration to mammals. Typically, the
10 analog polypeptide will be administered in the form of a composition comprising a purified form of the polypeptide (which may be chemically modified) in conjunction with one or more physiologically acceptable carriers, excipients, or diluents. Neutral buffered
15 saline or saline mixed with serum albumin are exemplary appropriate carriers. Other standard carriers, diluents, and excipients may be included as desired.

The pharmaceutical compositions of this invention
20 may be prepared for storage by mixing the selected composition having the desired degree of purity with optional physiologically acceptable carriers, excipients, or stabilizers (Remington's Pharmaceutical Sciences, 18th edition, A.R. Gennaro, ed., Mack
25 Publishing Company, 1990) in the form of a lyophilized cake or an aqueous solution. Acceptable carriers, excipients or stabilizers are nontoxic to recipients and are preferably inert at the dosages and concentrations employed, and include buffers such as phosphate,
30 citrate, acetate, succinate or other organic acid salts; antioxidants such as ascorbic acid; low molecular weight polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine,
35 glutamine, asparagine, arginine or lysine;

- 18 -

monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium;
5 and/or nonionic surfactants such as Tween, Pluronic or polyethylene glycol (PEG).

Any composition of this invention which is intended to be used for *in vivo* administration must be sterile.
10 Sterilization is readily accomplished by filtration through sterile filtration membranes. Where the composition is lyophilized, sterilization using these methods may be conducted either prior to, or following, lyophilization and reconstitution. The composition for
15 parenteral administration ordinarily will be stored in lyophilized form or in solution.

The amount of polypeptide that will be effective in the treatment of a particular disorder or condition will
20 depend on the nature of the polypeptide and disorder or condition, as well as the age and general health of the recipient, and can be determined by standard clinical procedures. Where possible, it will be desirable to determine the dose-response curve of the pharmaceutical
25 composition first *in vitro*, as in bioassay systems, and then in useful animal model systems *in vivo* prior to testing in humans. In general, suitable *in vivo* amounts can be developed based on a knowledge of the therapeutically effective doses known for the wild type
30 protein on which the analogs are based. The skilled practitioner, considering the therapeutic context, type of disorder under treatment, etc., will be able to ascertain proper dosing without undue effort.

- 19 -

Methods of introduction for administration purposes include intradermal, intramuscular, intraperitoneal, intravenous, and subcutaneous. In addition, the invention also encompasses pharmaceutical compositions comprising the polypeptide analogs administered via liposomes, microparticles or microcapsules, which may be particularly useful to achieve sustained release.

Special delivery devices may be needed in the case of some of the polypeptide analogs, such as those of NT-3, BDNF and other neurotrophic factors intended for the treatment of neurological conditions associated with the brain and other areas of the central nervous system. Such devices may include implants and osmotic pumps for intrathecal and intracranial delivery, for instance.

The analogs of this invention can also be used in accordance with standard procedures to generate antibodies that are useful for medically related purposes, such as for the monitoring of blood levels of the corresponding analog in a subject undergoing therapeutic treatment. Various procedures known in the art can be employed for the production of polyclonal antibodies that recognize epitopes of the polypeptides. For the production of antibody, various host animals can be immunized by injection with an analog polypeptide, or fragment or derivative thereof, including but not limited to rabbits, mice, rats, etc. Various adjuvants may be used to increase the immunological response, depending on the host species, including but not limited to Freund's, mineral gels such as aluminum hydroxide (alum), surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and

- 20 -

potentially useful human adjuvants such as Bacille Calmette-Guerin and *Corynebacterium parvum*.

For the preparation of monoclonal antibodies
5 directed toward the analog polypeptides, any technique which provides for the production of antibody molecules by continuous cell lines in culture may be used. For example, the hybridoma technique originally developed by Kohler and Milstein and described in Nature, Volume 256,
10 pages 495-497 (1975), as well as the trioma technique, the human B-cell hybridoma technique described by Kozbor et al in Immunology Today, Volume 4, page 72 (1983), and the EBV-hybridoma technique to produce monoclonal antibodies described by Cole et al in "Monoclonal
15 Antibodies and Cancer Therapy", Alan R. Liss, Inc., pages 77-96 (1985), are all useful for preparation of monoclonal antibodies.

In addition, a molecular clone of an antibody to an
20 epitope or epitopes of the polypeptide can be prepared with known techniques. In particular, recombinant DNA methodology may be used to construct nucleic acid sequences which encode a monoclonal antibody molecule or antigen-binding region thereof; see, for example,
25 Maniatis et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York (1982).

The antibodies are useful for both *in vivo* and *in*
30 *vitro* diagnostic purposes, particularly in labeled form to detect the presence of the polypeptides in a fluid or tissue sample.

- 21 -

DESCRIPTION OF SPECIFIC EMBODIMENTS

The invention is described in further detail with reference to the following materials, methods, procedures and test results. Amino acid residues of proteins are identified the in conventional manner using the established three letter designations (for example, "met" for methionine, "val" for valine, etc.) or in some cases the established single letter designations (for example, "M" for methionine, "R" for arginine, etc.) throughout the text.

Materials and Methods:

Preparation of NT-3 analogs. Amino acid residues for substitution in the native sequence of human NT-3 were selected with the aim of preserving the core structure and biological/therapeutic activity (see Holland et al., J. Mol. Biol., Volume 239, pages 385-400, 1994; Ibanez et al., in Cell, Volume 69, pages 329-341, 1992 and also in EMBO Journal, Volume 12, pages 2281-2293, 1993). The actual substitutions that were made in the native sequence of human NT-3 are reflected in the sequences shown in Figures 2 and 3, respectively. In one analog, shown in Figure 2, the following two substitutions were made: arginine at position 61 (arg₆₁) was replaced by alanine (ala), and lysine at position 64 (lys₆₄) was replaced by aspartic acid (asp). This analog was designated "NT-3₍₁₋₁₁₉₎ R61A,K64D". A second analog, shown in Figure 3, had these same two amino acid substitutions and, in addition, was truncated at residue 117 (thus deleting arg₁₁₈ and thr₁₁₉). This analog was designated "NT-3₍₁₋₁₁₇₎R61A,K64D". To create these analogs, the mutations were introduced in the sequence of human NT-3 by standard Polymerase Chain Reaction

- 22 -

(PCR) technology. For NT-3₍₁₋₁₁₉₎R61A,K64D, chemically synthesized oligonucleotides were used in pairs to create fragments of the NT-3 gene comprising the front portion up to the site of the mutations at the codons
5 corresponding to positions 61 and 64 and the back portion of the gene from the mutant codons to the end. A second PCR was carried out combining the front and back portions to create the full length nucleic acid molecule encoding the two mutations at positions 61 and
10 64, respectively. For NT-3₍₁₋₁₁₇₎R61A,K64D, the foregoing procedure was repeated, except the back portion omitted the codons for arginine and threonine at positions 118 and 119.

15 Expression in E. coli. To express the analogs in *E. coli*, a DNA sequence encoding for a methionine residue was included at the 5' end and a stop codon was placed at the 3' end in each case. In addition, cutting sites for the restriction enzymes XbaI and HindIII were
20 placed at the extreme 5' and 3' ends of the gene, respectively, and a synthetic ribosome binding site was placed an appropriate distance upstream of the initiating methionine. The resulting synthetic gene fragments, flanked by XbaI and HindIII restriction sites
25 at the 5' and 3' ends, respectively, contained a ribosome binding site, the ATG start codon (encoding methionine), the sequence encoding the analog, and a stop codon. The fragments were digested with restriction endonucleases NdeI and BamHI, and then
30 ligated into the vector pAMG12.

The expression plasmid pAMG12 can be derived from the plasmid pCFM1656 (ATCC Accession No. 69576, deposited February 24, 1994) by making a series of site
35 directed base changes by PCR overlapping oligo

- 23 -

mutagenesis and DNA sequence substitutions. Starting with the BglII site (plasmid base pair no. 180) immediately 5' to the plasmid replication promoter P_{copB} and proceeding toward the plasmid replication genes, the 5 base pair (bp) changes are as follows:

	<u>pAMG12 bp no.</u>	<u>bp in pCFM1656</u> <u>pAMG12</u>	<u>bp changed to in</u>
	# 204	T/A	C/G
10	# 428	A/T	G/C
	# 509	G/C	A/T
	# 617	- -	insert two G/C bp
	# 679	G/C	T/A
	# 980	T/A	C/G
15	# 994	G/C	A/T
	# 1004	A/T	C/G
	# 1007	C/G	T/A
	# 1028	A/T	T/A
	# 1047	C/G	T/A
20	# 1178	G/C	T/A
	# 1466	G/C	T/A
	# 2028	G/C	bp deletion
	# 2187	C/G	T/A
	# 2480	A/T	T/A
25	# 2499-2502	<u>AGTG</u> TCAC	<u>GTCA</u> CAGT
	# 2642	<u>TCCGAGC</u> AGGCTCG	bp deletion
30			
	# 3435	G/C	A/T
	# 3446	G/C	A/T
	# 3643	A/T	T/A
35			

- 24 -

In addition, the DNA sequence between the unique AatII (position #4364 in pCFM1656) and SacII (position #4585 in pCFM1656) restriction sites is substituted with the following DNA sequence:

5 [AatII sticky end]

5' CGTAACGTATGCATGGTCTCCCCATGCGAGAGTAGGGAACTGCCAGGCATCAA-
 3' GCACGCATTGCATACGTACCAGAGGGGTACGCTCTCATCCCTTGACGGTCCGTAGTT-

10 -TAAAACGAAAGGCTCAGTCGAAAGACTGGGCCCTTTCGTTTTATCTGTTGTTTGTCTGGTG-
 -ATTTTGCCTTCCGAGTCAGCTTCTGACCCGGAAAGCAAAATAGACAACAAACAGCCAC-

15 -ACGCTCTCCTGAGTAGGACAAATCCGCCGGGAGCGGATTTGAACGTTGCGAAGCAACGG-
 -TGCGAGAGGACTCATCCTGTTTAGGCGGCCCTCGCCTAAACTTGCAACGCTTCGTTGCC-

-CCGGAGGGTGGCGGGCAGGACGCCCGCCATAAACTGCCAGGCATCAAATTAAGCAGAAG
 -GGCCTCCACCGCCCGTCTGCGGGCGGTATTTGACGGTCCGTAGTTTAATTCTGCTTC-

20 -CCATCCTGACGGATGGCCTTTTTGCGTTTCTACAAACTCTTTTGTATTATTTTCTAAAT-
 -CGGTAGGACTGCCTACCGGAAAAACGCAAAGATGTTTGAGAAAACAAATAAAAAGATTTA

AatII

25 -ACATTCAAATATGGACGTCTCATAATTTTTTAAAAAATTCATTTGACAAATGCTAAAATTC-
 -TGTAAGTTTATACCTGCAGAGTATTAAAAATTTTAAAGTAAACTGTTTACGATTTTAAG-

-TTGATTAATATTCTCAATTGTGAGCGCTCACAAATTTATCGATTTGATTCTAGATTTGAGT-
 AACTAATTATAAGAGTTAACACTCGCGAGTGTTAAATAGCTAAACTAAGATCTAAACTCA

30 -TTTAACTTTTAGAAGGAGGAATAACATATGGTTAACGCGTTGGAATTCGAGCTCACTAGT-
 -AAATTGAAAATCTTCCTCCTTATTGTATACCAATTGCGCAACCTTAAGCTCGAGTGATCA-

SacII

35 -GTCGACCTGCAGGGTACCATGGAAGCTTACTCGAGGATCCGCGGAAAGAAGAAGAAG-
 -CAGCTGGACGTCCCATGGTACCTTCGAATGAGCTCCTAGGCGCCTTCTTCTTCTTCTTC-

-AAGAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAA-
 -TTCTTTCGGGCTTTCCTTCGACTCAACCGACGACGGTGGCGACTCGTTATTGATCGTATT-

40 -CCCCTTGGGGCTCTAAACGGGTCTTGAGGGGTTTTTTGCTGAAAGGAGGAACCGCTCTT-
 -GGGGAACCCCGAGATTTGCCCAAGAACTCCCCAAAAAACGACTTTCCTCCTTGCGGAGAA-

-CACGCTCTTCACGC 3'
 -GTGCGAGAAGTG 5'

45 [SacII sticky end]

The ligation product was transformed into competent host cells of *E. coli* strain FM15. Resulting colonies were screened for the production of recombinant protein

- 25 -

and those colonies producing the correct-sized protein were verified by DNA sequencing. The correct strain was inoculated for fermentation by transferring a small amount to Luria Broth (10 g/l of Trypticase-Peptone, 10 g/l of Yeast Extract, and 5 g/l of sodium chloride) and incubating at 30°C for sixteen hours with stirring at 250 rpm. The culture was transferred to sterile medium that had been sterilized in place in a fermentor, then the mass of the cells was increased using continuous feeds of glucose and organic nitrogen, before being induced with lactose. After induction, the fermentation was halted, the cells were harvested by centrifugation, the supernatant was removed, and the remaining cell paste was frozen.

Protein purification. Cells from the paste were broken by high pressure homogenization and inclusion bodies were recovered by centrifugation. The inclusion bodies were solubilized in guanidine-HCl, then diluted into urea. After standing for several days, the solution was adjusted to pH 3, diluted with water, centrifuged, and eluted in series through cation exchange and hydrophobic interaction chromatography columns. The peak fractions were pooled and sterile filtered.

Isoelectric point and protein charge. The isoelectric points of wild type human NT-3 (r-metHuNT-3, SEQ ID NO:1), and of the analogs thereof (i.e., SEQ ID NOS: 3 and 5) were calculated using the "GCG" protein/DNA Sequence Analysis Software Package available from Genetics Computer Group, Inc., Madison, Wisconsin. The charge of the molecule at physiological pH (assumed to be pH 7.4) was estimated using the same software. The pI of the first analog, NT-3₍₁₋₁₁₉₎R61A,K64D (SEQ ID NO: 3), was calculated to be about 0.9 pH units below

- 26 -

that of wild type NT-3 (8.5, compared to 9.4). The charge at physiologic pH (7.4) for this analog represented a reduction of about 2.5 pH units from that of wild type NT-3 (i.e., from approximately +7 to +4.5).
5 The pI for the other analog, NT-3₍₁₋₁₁₇₎R61A,K64D (SEQ ID NO: 5) was calculated to be approximately 8.2, which was about 1.2 pH units lower than the pI of wild type NT-3 (9.4). Moreover, the charge at physiologic pH for this analog was decreased by approximately 3.5 pH units, to
10 about +3.5, relative to wild type NT-3 (+7).

ELISA Assay. The ELISA assay was conducted on 96-well plates coated with a monoclonal antibody raised against human NT-3. A rabbit polyclonal antibody conjugated to
15 horse radish peroxidase was used as the secondary antibody. Serum samples, calibration standards, and quality control samples were diluted with phosphate buffer to a 50% serum matrix before assay. The sample size was 100 microliters (μ l) per well. Each sample was
20 assayed in duplicate. The limits of quantification were 0.65, 4.00, and 4.05 ng/ml of serum for wild type NT-3, NT-3₍₁₋₁₁₉₎R61A,K64D and NT-3₍₁₋₁₁₇₎R61A,K64D, respectively.

25 Size Exclusion Chromatography (SEC-HPLC). Size exclusion chromatography on each sample was performed using a Waters 600 system in conjunction with a G2000SWXL column (TosoHaas). Samples were eluted at a flow rate of 0.7 milliliters per minute (ml/min) in a
30 buffer consisting of 100 mM sodium phosphate, 0.5 M NaCl, pH 6.09. Peaks were detected at a wavelength of 230 nanometers (nm).

- 27 -

Cation Exchange Chromatography (CEX-HPLC). CEX-HPLC was performed using a Waters 625 system with a Resource S column (Pharmacia, Uppsala, Sweden). Samples were eluted at a flow rate of one milliliter per minute using
5 a sodium chloride gradient from 0 - 1 M in 20 mM Tris HCl, pH 8.5. Peaks were detected using a wavelength of 220 nm.

Silver Stained SDS-PAGE. Proteins were diluted with 2%
10 SDS, mixed with sample buffer, and heated for five minutes in boiling water. The separation was conducted according to manufacturer's instructions using precast TRIS-Tricine gradient gels, 10-20%, from ISS (Integrated Separations Systems, Natick, MA). Silver staining was
15 done according to the procedure of Blum et al. in Electrophoresis, Volume 8, pages 93-99 (1987).

Mitogenic Bioassay With 3T3trkC Cells. The biological activity of r-metHuNT-3 as a reference standard is
20 determined by means of a cell mitogenic bioassay utilizing 3T3trkC cells. These cells are created by transfecting 3T3 cells (ATCC), which normally do not express trkC receptor on their surface, with plasmid pcDNA1/neo (Invitrogen, San Diego, CA) modified to
25 contain the DNA sequence for human trkC receptor protein. See Shelton et al., Journal of Neuroscience, Volume 15, pages 477-491 (1995) for the sequence of the trkC gene, and Valenzuela et al., Neuron, Volume 10, pages 963-974 (1993) for an illustrative transfection
30 procedure. The transfected cells are maintained at $37 \pm 2^\circ\text{C}$, in a high humidity incubator under an atmosphere containing $5.5 \pm 1.0\%$ CO_2 and in Dulbecco's Minimum Essential Medium with fetal bovine serum and G-418 Sulfate. The cells are distributed into 96-well plates
35 for each assay. After approximately twenty four hours

- 28 -

of incubation time under the same conditions, the maintenance medium is replaced with RPMI 1640 and test samples are added. Varying concentrations of a standard and a test sample of r-metHuNT-3 are prepared in RPMI
5 1640 and added to the appropriate wells. The plates are returned to the incubator for approximately twenty four hours, then the cells are stained for viability with 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)2H-tetrazolium salt (MTS), a
10 tetrazolium compound. The plates are returned to the incubator for approximately five hours, after which the optical density of each well is read at 490 nm. A dose-response standard curve is constructed and a linear regression analysis is performed on the linear portion
15 of the standard curve. The concentration of test sample dilutions falling within the linear extracted range of the standard curve are then determined.

In Vivo Biological Testing. The effect of amino acid
20 changes on the biological properties of a molecule was evaluated *in vivo* in male Sprague Dawley rats, using a "cross-over" test design. In particular, nine animals were divided into three groups of three rats each, and the rats were administered wild type NT-3, NT-3₍₁₋₁₁₉₎
25 R61A,K64D, or NT-3₍₁₋₁₁₇₎R61A,K64D at a dose of 1 milligram per kilogram of body weight (mg/kg) each. The test material was administered either (1) intravenously (IV) as a first dose, then subcutaneously (SC) at twenty four hours after the first dose, or (2) in the reverse
30 manner. Serial blood samples were collected before dosing and at 1, 5, 15, and 30 minutes, and 1, 2, 4, and 8 hours after an IV dose. Following subcutaneous dosing, samples were collected at 10 and 30 minutes, and at 1, 2, 4, and 8 hours. Blood serum concentrations of
35 NT-3 were determined using an ELISA assay (see above).

- 29 -

The antibodies used in the assays were specific for quantitation of wild type NT-3. Though not fully optimized, the antibodies displayed sufficient cross-reactivity with NT-3₍₁₋₁₁₉₎R61A,K64D and NT-3₍₁₋₁₁₇₎

5 R61A,K64D to allow for quantitation of these analogs also. Standard curves were prepared for each protein (see Figure 4).

Test Results:

10

Characterization of NT-3 analogs. Both of the analogs, NT-3₍₁₋₁₁₉₎R61A,K64D and NT-3₍₁₋₁₁₇₎ R61A,K64D, were seen to retain the activity of wild-type NT-3 (r-metHuNT-3) in the PC-12 *in vitro* bioassay (Table 1). In fact, the
15 bioactivity of the analogs as evaluated in this assay appeared to be somewhat greater than that of wild-type NT-3, perhaps indicating an increased affinity for the trkC (NT-3) receptor.

20

Table 1. In Vitro Bioactivity of NT-3 Proteins

NT-3 Analog	Concentration submitted (mg/ml)	Measured concentration (mg/ml)	Percentage of expected activity (%)
Wild-type NT-3	0.32	0.23	72
NT-3 ₍₁₋₁₁₇₎ R61A,K64D	0.36	1.18	328
NT-3 ₍₁₋₁₁₉₎ R61A,K64D	0.25	1.31	524

Both analogs eluted as noncovalent dimers on size exclusion-HPLC, the same as for wild type NT-3 (see
25 Figure 5). As expected, there was no significant

- 30 -

difference in the molecular weights of the three proteins. No significant protein aggregation was detected for either analog. The results of cation exchange-HPLC (see Figure 6) were consistent with a reduction in pI for both analogs. The change in protein charge probably accounts for slight shifts in the SDS-PAGE (Figure 7), compared to wild type NT-3. Both of the analogs retain the biological activity and noncovalent dimer structure of wild type NT-3.

Pharmacokinetic Behavior. Serum concentration curves following intravenous administration were seen to be biphasic (see Figure 8). There was a significant difference in the initial distribution phase among the various NT-3 types. The half lives ($\alpha T_{1/2}$) were 3.3, 5.4 and 7.6 minutes for wild type NT-3, NT-3₍₁₋₁₁₉₎R61A,K64D, and NT-3₍₁₋₁₁₇₎ R61A,K64D, respectively (see Table 2, below). The observed decrease in clearance following intravenous administration could be due solely to the slower distribution of the NT-3 analogs. The most pronounced decrease in concentration during this phase was observed with wild type NT-3. The terminal phase half lives ($\beta T_{1/2}$) were similar for the three types and ranged from 0.9 to 1.0 hours, suggesting that the elimination mechanism for these types could be the same. The areas under the concentration-time curves (t-AUCinf) for NT-3₍₁₋₁₁₇₎ R61A,K64D and NT-3₍₁₋₁₁₉₎R61A,K64D were approximately 1.2 to 2-fold that of wild type NT-3.

- 31 -

Table 2. Pharmacokinetic Parameters Obtained in Rats Given a Single IV Dose of 1mg/kg of NT-3 Proteins

NT-3 Type	t-AUC(inf) ¹ (ng-hr/ml)	CL ² (ml/kg-hr)	$\alpha T_{1/2}$ ³ (min)	$\beta T_{1/2}$ ⁴ (hr)
Wild type	724.1 \pm 151.0	1411.7 \pm 294.4	3.3 \pm 0.3	1.0 \pm 0.6
NT-3(1-119) R61A,K64D	880.7 \pm 320.3	1276.2 \pm 581.8	5.4 \pm 1.9	0.9 \pm 0.6
NT-3(1-117) R61A,K64D	1420.7 \pm 117.9	706.3 \pm 58.7	7.6 \pm 0.0	1.0 \pm 0.0

- 5 1 Area under the serum concentration time curve from time zero to infinity. Area calculation is by trapezoidal method.
 2 Clearance rate is calculated by: Dose \div AUC.
 3 Distribution phase half life ($\alpha T_{1/2}$).
 10 4 Terminal phase half life ($\beta T_{1/2}$).

Following subcutaneous injection, the serum concentration increases rapidly for wild type NT-3 (see Figure 9). The time to maximum concentration (T_{MAX}) was approximately 0.17 hour (see Table 3, below). A slower absorption profile was observed for the modified types. Specifically, T_{MAX}'s for NT-3(1-119) R61A,K64D and NT-3(1-117)R61A,K64D were 0.67 and 1.33 hours, respectively. The maximum concentrations for NT-3(1-119) R61A,K64D and NT-3(1-117)R61A,K64D were 6 to 10 times higher than for wild type NT-3, suggesting that the analogs manifested a greater degree of absorption from the site of injection following administration. Furthermore, the degree or extent of absorption (bioavailability) is more typically determined from the ratio of the areas under the serum curves for subcutaneous and intravenous routes of administration, Table 3. The bioavailability for wild type NT-3, NT-3(1-119) R61A,K64D, and NT-3(1-117)R61A,K64D was 2.2, 28.5 and 43.22%, respectively. The terminal half lifes

- 32 -

for the analogs appear to be longer than that of the wild type.

Table 3. Pharmacokinetic Parameters Obtained in Rats Given a Single SC Dose of 1mg/kg of NT-3 Proteins

NT-3 Type	t-AUC(inf) ¹ (ng-hr/ml)	F ² (%)	C _{MAX} ³ (ng/ml)	T _{MAX} ⁴ (hr)	$\beta_{T_{1/2}}$ ⁵ (hr)
Wild type	15.2 ± 9.5	2.2 ± 1.3	17.8 ± 11.6	0.2 ± 0.0	0.4 ± 0.0
NT-3 (1-119) R61A, K64D	241.3 ± 74.8	28.5 ± 6.3	106.5 ± 47.1	0.7 ± 0.3	1.4 ± 0.6
NT-3 (1-117) R61A, K64D	632.9 ± 38.0	43.2 ± 2.0	180.1 ± 51.2	1.3 ± 0.6	1.4 ± 0.8

- 1 Area under the serum concentration time curve from time zero to infinity. Area calculation is by trapezoidal method.
- 2 Bioavailability (F) is calculated by: $(t\text{-AUC}_{SC} + t\text{-AUC}_{IV}) \times 100\%$, where both areas were obtained from the same animal.
- 3 C_{MAX} is the maximal concentration.
- 4 T_{MAX} is the time to maximal concentration.
- 5 Terminal phase half life ($\beta_{T_{1/2}}$).

The results from these studies show that by decreasing the pI of NT-3, one can lower the clearance rate following intravenous administration, at least initially, and also enhance the extent of absorption following subcutaneous administration. These results also demonstrate that the charge of the protein plays a significant role in determining pharmacokinetic behavior. In the case of a basic protein such as NT-3, as well as other cationic proteins, decreasing the isoelectric point (or the charge at physiological pH) can lead to significant improvement in the absorption and bioavailability of the molecule following subcutaneous administration. From this knowledge, and the description provided herein, it is possible to design new molecules of improved therapeutic value.

- 33 -

It should be noted that the analogs illustrated in the foregoing description are intended to be exemplary only, and that additional analogs of NT-3, as well as of other proteins, can be created in light of the present description to achieve lower isoelectric points with longer circulation times and/or higher absorption. In one variation, for instance, the particular analog proteins of SEQ ID NOS: 3 and 5 can be produced by expressed in a mammalian cell or a secreting bacterial strain such that a "met-less" product is obtained (i.e., the methionine residue at the N-terminus is processed away, to result in the polypeptides of SEQ ID NOS: 6 and 7, respectively).

BDNF Analogs

Using the procedures described above for NT-3, the following analogs of BDNF were prepared and purified from *E.coli* and the isoelectric point (pI) and (approximate) net charge at physiological pH (7.4) were measured for each. The pI and charge at physiological pH for "wild type" BDNF (i.e., of naturally occurring sequence; see U.S. Patent No. 5,180,820, Figure 5) are also shown for purposes of comparison. Positions for substitution are numbered beginning with the first residue following methionine in the mature form of the protein as expressed in *E. coli*. (i.e., the initial methionine residue is not counted).

BDNF, K65D, K73D, K95A, R97A

Substitutions were lysine to aspartic acid at positions 65 and 73, lysine to alanine at position 95, and arginine to alanine at position 97.

- 34 -

Calculated pI: 8.46

Charge: +4.0

BDNF, P60E, K65D, K73D, K95A

- 5 Substitutions were proline to glutamic acid at position 60,
lysine to aspartic acid at positions 65 and 73, and
lysine to alanine at position 95.

10 Calculated pI: 8.45

Charge: +4.0

Wild Type BDNF

Calculated pI: 10.23

15 Charge: +9.5

Biological Test Results and Characterization

- 20 1) In Vitro Bioactivity: Mitogenic Bioassay with
PC12/trkC Cells. In this assay, the biological activity
of wild type BDNF and the BDNF analogs is determined
quantitatively by measuring the incorporation of (MTS)
into PC-12 cells (ATCC) that have been transformed to
25 express trkB receptor (the high affinity receptor for
BDNF). The transformed cells are maintained at $37 \pm$
 2°C , in a high humidity incubator under an atmosphere
containing $7.5 \pm 1\%$ carbon dioxide, in Dulbecco's
Minimum Essential Medium containing fetal bovine serum
30 and horse serum and 1% L-glutamine. The cells are
distributed into well plates for assaying, and
incubation is continued. After approximately forty eight
hours, the maintenance medium is replaced with RPMI 1640
Medium, the test samples are added, and incubation is

- 35 -

continued under the same conditions for another forty eight hours. The cells are then stained with MTS, incubated under the same conditions for another five hours, and the optical density for each well is read with a microplate reader at 490 nm. The results for bioactivity of the two BDNF analogs versus wild type BDNF are given in Table 4, below.

Table 4. In Vitro Bioactivity of BDNF Proteins

	Bioactivity (mg/mg)
Wild-type BDNF	0.61
BDNF, K65D, K73D, K95A, R97A	1.24
BDNF, P60E, K65D, K73D, K95A	0.61

2) In Vivo Biological Testing and Results. The biological properties of the analogs were evaluated in vivo in male Sprague Dawley rats at a dose of 3.0 milligrams per kilogram of body weight for BDNF, K65D, K73D, K95A, R97A and 1.7 milligrams per kilogram of body weight for BDNF, P60E, K65D, K73D, K95A. The test materials were administered intravenously and subcutaneously, followed by collection of blood samples and measurement of blood serum concentrations (see same procedure described above for NT-3 and NT-3 analogs). The pharmacokinetic behavior is given below with respect to each form of administration.

- 36 -

Table 5. Pharmacokinetic Properties in Rats,
Single Intravenous (IV) Dose of BDNF Proteins

BDNF Type	t-AUC(inf) (ng-hr/ml)
Wild type	8652.8 ± 833.6
BDNF, K65D, K73D, K95A, R97A	12932.8 ± 913.0
BDNF, P60E, K65D, K73D, K95A	14097.2 ± 949.8

5

Table 6. Pharmacokinetic Properties in Rats,
Single Subcutaneous (SC) Dose of BDNF Proteins

BDNF Type	t-AUC(inf) (ng-hr/ml)	F (%)
Wild type	462.5 ± 130.3	4.7 ± 2.0
BDNF, K65D, K73D, K95A, R97A	2401.6 ± 297.1	16.8 ± 0.1
BDNF, P60E, K65D, K73D, K95A	2049.2 ± 357.4	13.9 ± 2.0

10

These results show that the introduction of the mutations into wild type BDNF has a measurable effect on pharmacokinetic properties. In particular, greater *in vivo* bioavailability is achieved for the two BDNF analogs in comparison with wild type BDNF as reflected by the increased values for t-AUC(inf) following intravenous administration and the increase in t-AUC(inf) and F% following subcutaneous administration.

15

The invention is defined in the appended claims.

- 37 -

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Boone, Thomas C.
Cheung, Ellen N.
Hershenson, Susan I.
Young, John D.
- (ii) TITLE OF INVENTION: PROTEIN ANALOGS WITH EXTENDED
CIRCULATION TIMES
- (iii) NUMBER OF SEQUENCES: 7
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Amgen Inc.
 - (B) STREET: 1840 DeHavilland Drive
 - (C) CITY: Thousand Oaks
 - (D) STATE: California
 - (E) COUNTRY: USA
 - (F) ZIP: 91320-17889
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE:
 - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Mazza, Richard J.
 - (C) REFERENCE/DOCKET NUMBER: A-411

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 120 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: unknown
- (ii) MOLECULE TYPE: protein

- 38 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Met	Tyr	Ala	Glu	His	Lys	Ser	His	Arg	Gly	Glu	Tyr	Ser	Val	Cys	Asp	
1				5					10					15		
Ser	Glu	Ser	Leu	Trp	Val	Thr	Asp	Lys	Ser	Ser	Ala	Ile	Asp	Ile	Arg	
			20					25					30			
Gly	His	Gln	Val	Thr	Val	Leu	Gly	Glu	Ile	Lys	Thr	Gly	Asn	Ser	Pro	
		35					40					45				
Val	Lys	Gln	Tyr	Phe	Tyr	Glu	Thr	Arg	Cys	Lys	Glu	Ala	Arg	Pro	Val	
		50				55					60					
Lys	Asn	Gly	Cys	Arg	Gly	Ile	Asp	Asp	Lys	His	Trp	Asn	Ser	Gln	Cys	
65					70					75					80	
Lys	Thr	Ser	Gln	Thr	Tyr	Val	Arg	Ala	Leu	Thr	Ser	Glu	Asn	Asn	Lys	
			85						90					95		
Leu	Val	Gly	Trp	Arg	Trp	Ile	Arg	Ile	Asp	Thr	Ser	Cys	Val	Cys	Ala	
			100					105					110			
Leu	Ser	Arg	Lys	Ile	Gly	Arg	Thr									
			115				120									

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 360 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

ATGTACGCTG AACACAAATC TCACCGTGGT GAATACTCTG TTTGCGACTC TGAATCTCTG	60
TGGGTTACCG ACAAATCTTC TGCTATCGAC ATCCGTGGTC ACCAGGTTAC CGTTCTGGGT	120
GAAATCAAAA CCGGTAATC TCCGGTTAAA CAGTACTTCT ACGAAACCCG TTGCAAAGAA	180
GCTGCACCGG TTGACAACGG TTGCCGTGGT ATCGACGACA AACACTGGAA CTCTCAGTGC	240
AAAACCTCTC AGACCTACGT TCGTGCTCTG ACCTCTGAAA ACAACAAGCT TGTGTTGGTTGG	300
CGTTGGATTTC GTATCGACAC CTCTTGCGTT TGCCTCTGT CTCGTAAAAT CGGTTCGTACC	360

- 39 -

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 120 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Met	Tyr	Ala	Glu	His	Lys	Ser	His	Arg	Gly	Glu	Tyr	Ser	Val	Cys	Asp	1	5	10	15
Ser	Glu	Ser	Leu	Trp	Val	Thr	Asp	Lys	Ser	Ser	Ala	Ile	Asp	Ile	Arg	20	25	30	
Gly	His	Gln	Val	Thr	Val	Leu	Gly	Glu	Ile	Lys	Thr	Gly	Asn	Ser	Pro	35	40	45	
Val	Lys	Gln	Tyr	Phe	Tyr	Glu	Thr	Arg	Cys	Lys	Glu	Ala	Ala	Pro	Val	50	55	60	
Asp	Asn	Gly	Cys	Arg	Gly	Ile	Asp	Asp	Lys	His	Trp	Asn	Ser	Gln	Cys	65	70	75	80
Lys	Thr	Ser	Gln	Thr	Tyr	Val	Arg	Ala	Leu	Thr	Ser	Glu	Asn	Asn	Lys	85	90	95	
Leu	Val	Gly	Trp	Arg	Trp	Ile	Arg	Ile	Asp	Thr	Ser	Cys	Val	Cys	Ala	100	105	110	
Leu	Ser	Arg	Lys	Ile	Gly	Arg	Thr									115	120		

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 354 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- 40 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

```

ATGTACGCTG AACACAAATC TCACCGTGGT GAATACTCTG TTTGCGACTC TGAATCTCTG      60
TGGGTTACCG ACAAATCTTC TGCTATCGAC ATCCGTGGTC ACCAGGTTAC CGTTCTGGGT      120
GAAATCAAAA CCGGTAATC TCCGGTTAAA CAGTACTTCT' ACGAAACCCG TTGCAAAGAA      180
GCTGCACCGG TTGACAACGG TTGCCGTGGT ATCGACGACA AACACTGGAA CTCTCAGTGC      240
AAAACCTCTC AGACCTACGT TCGTGCTCTG ACCTCTGAAA ACAACAAGCT' TGTTGGTTGG      300
CGTTGGATTTC GTATCGACAC CTCTTGCGTT TCGCTCTGTG CTCGTAAAAT CGGT          354

```

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 118 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

```

Met Tyr Ala Glu His Lys Ser His Arg Gly Glu Tyr Ser Val Cys Asp
1           5           10           15
Ser Glu Ser Leu Trp Val Thr Asp Lys Ser Ser Ala Ile Asp Ile Arg
          20           25           30
Gly His Gln Val Thr Val Leu Gly Glu Ile Lys Thr Gly Asn Ser Pro
          35           40           45
Val Lys Gln Tyr Phe Tyr Glu Thr Arg Cys Lys Glu Ala Ala Pro Val
          50           55           60
Asp Asn Gly Cys Arg Gly Ile Asp Asp Lys His Trp Asn Ser Gln Cys
          65           70           75           80
Lys Thr Ser Gln Thr Tyr Val Arg Ala Leu Thr Ser Glu Asn Asn Lys
          85           90           95
Leu Val Gly Trp Arg Trp Ile Arg Ile Asp Thr Ser Cys Val Cys Ala
          100          105          110
Leu Ser Arg Lys Ile Gly
          115

```

- 41 -

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 119 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Tyr	Ala	Glu	His	Lys	Ser	His	Arg	Gly	Glu	Tyr	Ser	Val	Cys	Asp	Ser	1	5	10	15
Glu	Ser	Leu	Trp	Val	Thr	Asp	Lys	Ser	Ser	Ala	Ile	Asp	Ile	Arg	Gly	20	25	30	
His	Gln	Val	Thr	Val	Leu	Gly	Glu	Ile	Lys	Thr	Gly	Asn	Ser	Pro	Val	35	40	45	
Lys	Gln	Tyr	Phe	Tyr	Glu	Thr	Arg	Cys	Lys	Glu	Ala	Ala	Pro	Val	Asp	50	55	60	
Asn	Gly	Cys	Arg	Gly	Ile	Asp	Asp	Lys	His	Trp	Asn	Ser	Gln	Cys	Lys	65	70	75	80
Thr	Ser	Gln	Thr	Tyr	Val	Arg	Ala	Leu	Thr	Ser	Glu	Asn	Asn	Lys	Leu	85	90	95	
Val	Gly	Trp	Arg	Trp	Ile	Arg	Ile	Asp	Thr	Ser	Cys	Val	Cys	Ala	Leu	100	105	110	
Ser	Arg	Lys	Ile	Gly	Arg	Thr										115			

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 117 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

- 42 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

[illegible]

- 43 -

CLAIMS

WHAT IS CLAIMED IS:

1. A polypeptide analog of a cationic polypeptide wherein the analog has an amino acid sequence that differs from the native sequence of the original polypeptide by one or more amino acid residues, or by chemical modification of one or more amino acid residues in the native sequence, such that the isoelectric point is lower and the *in vivo* circulating life and/or absorption is increased for the analog relative to those same properties in the unmodified cationic polypeptide.

2. A polypeptide according to claim 1, which is also characterized by a lower charge under physiological conditions compared to the unmodified cationic polypeptide.

3. A polypeptide according to claim 1, which is an analog of a cationic protein selected from the group consisting of neurotrophic factor-3 (NT-3), brain derived neurotrophic factor (BDNF), macrophage growth and differentiation factor (MGDF) and keratinocyte growth factor (KGF).

4. A polypeptide according to claim 3, which is an analog of NT-3.

5. A polypeptide according to claim 4, having the amino acid sequence of SEQ ID NO: 3.

6. A polypeptide according to claim 4, having the amino acid sequence of SEQ ID NO: 5.

- 44 -

7. A polypeptide according to claim 4, having the amino acid sequence of SEQ ID NO: 6.

8. A polypeptide according to claim 4, having the amino acid sequence of SEQ ID NO: 7.

9. A DNA molecule encoding a polypeptide analog of a cationic polypeptide wherein the analog has an amino acid sequence that differs from the native sequence of the original polypeptide by one or more amino acid residues, or by chemical modification of one or more amino acid residues in the native sequence, such that the isoelectric point is lower and the *in vivo* circulating life and/or absorption is increased for the analog relative to those same properties in the unmodified cationic polypeptide.

10. A DNA molecule according to claim 9 which encodes an analog of a cationic protein selected from the group consisting of NT-3, BDNF, MGDF and KGF.

11. A DNA molecule according to claim 10 which encodes a polypeptide analog of NT-3.

12. A DNA molecule according to claim 11 which encodes the polypeptide of SEQ ID NO: 3.

13. A DNA molecule according to claim 11 which encodes the polypeptide of SEQ ID NO: 5.

14. A DNA molecule according to claim 11 which has the nucleic acid sequence of SEQ ID NO: 2.

15. A DNA molecule according to claim 11 which has the nucleic acid sequence of SEQ ID NO: 4.

- 45 -

16. A biologically functional expression vector which includes a DNA molecule according to claim 9 operatively linked to expression regulatory sequences.

17. A prokaryotic or eukaryotic host cell transformed or transfected with an expression vector according to claim 16 in a manner allowing the host cell to express the polypeptide encoded by the DNA molecule.

18. A transformed or transfected bacterial host cell according to claim 17.

19. A transformed or transfected *E. coli* host cell according to claim 18.

20. A transformed or transfected mammalian host cell according to claim 17.

21. A transformed or transfected CHO cell according to claim 20.

22. A transformed or transfected COS cell according to claim 20.

23. A process for the production of a polypeptide analog of a cationic polypeptide, wherein the analog has an amino acid sequence that differs from the native sequence of the original polypeptide by one or more amino acid residues, such that the isoelectric point is lower and the *in vivo* circulating life and/or absorption is increased for the analog relative to those same properties in the unmodified cationic polypeptide, said process comprising culturing under suitable nutrient conditions a prokaryotic or eukaryotic host cell transformed or transfected with an expression vector comprising a DNA molecule encoding said polypeptide in a

- 46 -

manner allowing the host cell to express the polypeptide, and optionally isolating the polypeptide product of the expression.

24. A process according to claim 23, in which the polypeptide is an analog of NT-3.

25. A process according to claim 23 in which the DNA molecule has been prepared by site directed mutagenesis.

26. A process according to claim 23, in which the analog has the amino acid sequence of SEQ ID NO: 3.

27. A process according to claim 23, in which the analog has the amino acid sequence of SEQ ID NO: 5.

28. A process according to claim 23, in which the analog has the amino acid sequence of SEQ ID NO: 6.

29. A process according to claim 23, in which the analog has the amino acid sequence of SEQ ID NO: 7.

30. A process according to claim 23, in which the host cell is bacterial.

31. A process according to claim 30, in which the bacterial host cell is *E. coli*.

32. A polypeptide product of expression in a eukaryotic or prokaryotic host cell of a DNA molecule according to claim 9.

33. An antibody against a polypeptide according to claim 1.

- 47 -

34. An antibody according to claim 33 which is polyclonal.

35. An antibody according to claim 34 which is monoclonal.

36. A pegylated derivative of a polypeptide according to claim 1.

37. A pharmaceutical composition comprising a therapeutically effective amount of a polypeptide according to claim 1 and a pharmaceutically acceptable carrier or diluent.

38. A method for the treatment of peripheral neuropathies, comprising administering to a patient having the disorder a therapeutically effective amount of a polypeptide according to claim 4.

1 / 1 1

FIG. 1

Met Tyr Ala Glu His Lys Ser His Arg Gly Glu Tyr Ser Val Cys Asp
-1 5 10 15

Ser Glu Ser Leu Trp Val Thr Asp Lys Ser Ser Ala Ile Asp Ile Arg
20 25 30

Gly His Gln Val Thr Val Leu Gly Glu Ile Lys Thr Gly Asn Ser Pro
35 40 45

Val Lys Gln Tyr Phe Tyr Glu Thr Arg Cys Lys Glu Ala Arg Pro Val
50 55 60

Lys Asn Gly Cys Arg Gly Ile Asp Asp Lys His Trp Asn Ser Gln Cys
65 70 75

Lys Thr Ser Gln Thr Tyr Val Arg Ala Leu Thr Ser Glu Asn Asn Lys
80 85 90 95

Leu Val Gly Trp Arg Trp Ile Arg Ile Asp Thr Ser Cys Val Cys Ala
100 105 110

Leu Ser Arg Lys Ile Gly Arg Thr
115

2 / 1 1

FIG. 2A

ATGTACGCTG AACACAAATC TCACCGTGGT GAATACTCTG TTTGCGACTC TGAATCTCTG	60
TGGGTTACCG ACAAATCTTC TGCTATCGAC ATCCGTGGTC ACCAGGTAC CGTTCTGGGT	120
GAAATCAAAA CCGGTAAGTC TCCGGTTAAA CAGTACTTCT ACGAAACCCG TTGCAAAGAA	180
GCTGCACCGG TTGACAACGG TTGCCGTGGT ATCGACGACA AACACTGGAA CTCTCAGTGC	240
AAAACCTCTC AGACCTACGT TCGTGCTCTG ACCTCTGAAA ACAACAAGCT TGTGTTGGTGG	300
CGTTGGATTC GTATCGACAC CTCTTGCATT TCGCTCTGT CTCGTAAAAT CGGTCGTACC	360

3 / 1 1

FIG.2B

Met	Tyr	Ala	Glu	His	Lys	Ser	His	Arg	Gly	Glu	Tyr	Ser	Val	Cys	Asp	-1	5	10	15
Ser	Glu	Ser	Leu	Trp	Val	Thr	Asp	Lys	Ser	Ser	Ala	Ile	Asp	Ile	Arg	20	25	30	
Gly	His	Gln	Val	Thr	Val	Leu	Gly	Glu	Ile	Lys	Thr	Gly	Asn	Ser	Pro	35	40	45	
Val	Lys	Gln	Tyr	Phe	Tyr	Glu	Thr	Arg	Cys	Lys	Glu	Ala	Ala	Pro	Val	50	55	60	
Asp	Asn	Gly	Cys	Arg	Gly	Ile	Asp	Asp	Lys	His	Trp	Asn	Ser	Gln	Cys	65	70	75	
Lys	Thr	Ser	Gln	Thr	Tyr	Val	Arg	Ala	Leu	Thr	Ser	Glu	Asn	Asn	Lys	80	85	90	95
Leu	Val	Gly	Trp	Arg	Trp	Ile	Arg	Ile	Asp	Thr	Ser	Cys	Val	Cys	Ala	100	105	110	
Leu	Ser	Arg	Lys	Ile	Gly	Arg	Thr	115											

4 / 1 i

FIG.3A

ATGTACGCTG AACACAAATC TCACCGTGGT GAATACTCTG TTTGCGACTC TGAATCTCTG	60
TGGGTACCG ACAATCTTC TGCTATCGAC ATCCGTGGTC ACCAGGTAC CGTTCTGGGT	120
GAAATCAAAA CCGGTAATC TCCGGTAAA CAGTACTTCT ACGAAACCCG TTGCAAAGAA	180
GCTGCACCGG TTGACAACGG TTGCCGTGGT ATCGACGACA AACACTGGAA CTCTCAGTGC	240
AAAACCTCTC AGACCTACGT TCGTGCTCTG ACCTCTGAAA ACAACAAGCT TGTGGTTGG	300
CGTTGGATTG GTATCGACAC CTCTTGCGTT TCGCTCTGT CTCGTAAAAT CGGT	354

5 / 1 1

FIG.3B

Met Tyr Ala Glu His Lys Ser His Arg Gly Glu Tyr Ser Val Cys Asp
 -1 5 10 15

Ser Glu Ser Leu Trp Val Thr Asp Lys Ser Ser Ala Ile Asp Ile Arg
 20 25 30

Gly His Gln Val Thr Val Leu Gly Glu Ile Lys Thr Gly Asn Ser Pro
 35 40 45

Val Lys Gln Tyr Phe Tyr Glu Thr Arg Cys Lys Glu Ala Ala Pro Val
 50 55 60

Asp Asn Gly Cys Arg Gly Ile Asp Asp Lys His Trp Asn Ser Gln Cys
 65 70 75


Lys Thr Ser Gln Thr Tyr Val Arg Ala Leu Thr Ser Glu Asn Asn Lys
 80 85 90 95

Leu Val Gly Trp Arg Trp Ile Arg Ile Asp Thr Ser Cys Val Cys Ala
 100 105 110

Leu Ser Arg Lys Ile Gly
 115


6 / 1 1

FIG.4




7 / 11

FIG.5




8 / 1 1

FIG. 6




9 / 11

FIG. 7




10 / 11

FIG.8



11 / 11

FIG.9



INTERNATIONAL SEARCH REPORT

Interr. Application No
PCT/US 97/12609

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07K14/475 C07K1/107

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 93 18066 A (PERSSON HAAKAN BENGT ;MOLINER CARLOS FERNANDO IBANEZ (SE)) 16 September 1993	1-4, 9-11,16, 17,20, 22-25,32
Y	* see for example amended claims 1,2,5,10,11,14 * see page 9 - page 13 ---	18,19, 30,31,36
Y	WO 96 15146 A (AMGEN INC) 23 May 1996 see abstract; claims 1,3 see page 9, line 20 - page 10, line 16 --- -/-	18,19, 30,31,36

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

16 October 1997

Date of mailing of the international search report

18.11.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Cervigni, S

INTERNATIONAL SEARCH REPORT

Inter national Application No
PCT/US 97/12609

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 96 11951 A (AMGEN INC ;CHEN BAO LU (US); ARAKAWA TSUTOMU (US)) 25 April 1996</p> <p>see page 13 - page 14 see page 18, line 32 - page 21, line 24 * see also claims *</p> <p>---</p>	<p>1-3,9, 10, 16-21, 23,25, 30-37</p>
X	<p>EP 0 668 352 A (KIRIN BREWERY) 23 August 1995</p> <p>see page 11, line 5 - line 9 see page 98, line 41; claim 10 see page 99, line 36; claim 7 see claims 12,20,30,38</p> <p>---</p>	<p>1-3,9, 10, 16-23, 25,30-37</p>
A	<p>LOMKO I: "NEUROTROPHINS - AN UPDATE" DRUG NEWS AND PERSPECTIVES, vol. 6, no. 9, November 1993, pages 669-671, XP000647898 see the whole document</p> <p>---</p>	
A	<p>MAISONPIERRE P C ET AL: "HUMAN AND RAT BRAIN-DERIVED NEUROTROPHIC FACTOR AND NEUROTROPHIN-3: GENE STRUCTURES, DISTRIBUTIONS, AND CHROMOSOMAL LOCALIZATIONS" GENOMICS, vol. 10, no. 3, 1 July 1991, pages 558-568, XP000386393 see the whole document see page 558, column 2, line 27 - line 35</p> <p>-----</p>	

INTERNATIONAL SEARCH REPORT

I. International application No.
PCT/US 97/12609

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 97 12609

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

Claims Nos.: 38

because they relate to subject matter not required to be searched by this Authority, namely:

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

Remark : Although claim 38 is directed to a method of treatment of the human/animal body , the search has been carried out and based on the alleged effects of the compound/composition.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/12609

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9318066 A	16-09-93	US 5349055 A AU 674305 B CA 2131552 A CN 1079992 A EP 0632817 A JP 8511675 T US 5488099 A ZA 9301597 A	20-09-94 19-12-96 16-09-93 29-12-93 11-01-95 10-12-96 30-01-96 27-09-93
WO 9615146 A	23-05-96	AU 4107196 A EP 0792288 A NO 972176 A	06-06-96 03-09-97 14-07-97
WO 9611951 A	25-04-96	AU 3893195 A EP 0785950 A NO 971621 A AU 3707795 A AU 681546 B AU 3708395 A EP 0785948 A FI 971420 A FI 971536 A WO 9611949 A WO 9611950 A NO 971566 A NO 971568 A PL 319784 A	06-05-96 30-07-97 12-06-97 06-05-96 28-08-97 06-05-96 30-07-97 04-04-97 09-06-97 25-04-96 25-04-96 14-04-97 12-06-97 18-08-97
EP 0668352 A	23-08-95	AU 1671895 A BR 9505781 A CA 2160591 A CN 1131438 A EP 0695355 A FI 954889 A HU 75656 A JP 8228781 A WO 9521919 A JP 8277296 A JP 8291196 A JP 8510921 T	29-08-95 05-03-96 17-08-95 18-09-96 07-02-96 10-11-95 28-05-97 10-09-96 17-08-95 22-10-96 05-11-96 19-11-96

Information on patent family members

PCT/US 97/12609

11-12-95
18-03-96
30-04-96